@article{dce9551112164d4caf8506ce00534c18,
title = "Repeated vaccination against SARS-CoV-2 elicits robust polyfunctional T cell response in allogeneic stem cell transplantation recipients",
author = "Patrick Harrington and Doores, {Katie J.} and Chandan Saha and Jamie Saunders and Fiona Child and Richard Dillon and Sukran Saglam and Kavita Raj and Donal McLornan and Daniele Avenoso and Shahram Kordasti and Amy O'Reilly and Andreas Espehana and Thomas Lechmere and Hataf Khan and Malim, {Michael H.} and Claire Harrison and Varun Mehra and {de Lavallade}, Hugues",
note = "Funding Information: P.H. received research funding from Bristol Myers Squibb and speaker fees from Incyte. D.M. received speaker fees and advisory boards Novartis, Celgene, and Jazz pharmaceuticals. S.K. received Celgene and Novartis research grant and Alexion speaker honorarium. C.H. received speaker fees from Novartis, Jannsen, CTI, Celgene, and Medscape and has served on the advisory board for Incyte, CTI, Sierra Oncology, Novartis, Celgene, Roche, AOP Pharma, Geron, and Astra Zenica. H.d.L. has received grants and speakers fees from Bristol Myers Squibb and Incyte and speaker fees from Novartis. Funding Information: The authors acknowledge a Blood Cancer UK award to P.H. and H.d.L. (reference 21012), King's Together Rapid COVID-19 Call awards to M.H.M. and K.J.D. a Huo Family Foundation Award to M.H.M. and K.J.D. Chronic Disease Research Foundation award CDRF-22/2020 to K.J.D. and M.H.M. and Wellcome Trust Investigator Award 106223/Z/14/Z to M.H.M. C.G. was supported by the MRC-KCL Doctoral Training Partnership in Biomedical Sciences (MR/N013700/1). Fondation Dormeur, Vaduz funded equipment to K.J.D. P.H. and H.d.L. designed the research, performed the research, analyzed the data, and wrote the manuscript. K.J.D. T.L. H.K. and M.M. performed the research and reviewed the manuscript. F.C. R.D. S.S. K.R. D.M. D.A., DA, S.K. C.H. and V.M. assisted with patient recruitment and reviewed the manuscript. C.S. J.S. A.O.R. and A.E. assisted with patient recruitment and patient interviews and reviewed the manuscript. V.M. and H.d.L. share senior authorship. P.H. received research funding from Bristol Myers Squibb and speaker fees from Incyte. D.M. received speaker fees and advisory boards Novartis, Celgene, and Jazz pharmaceuticals. S.K. received Celgene and Novartis research grant and Alexion speaker honorarium. C.H. received speaker fees from Novartis, Jannsen, CTI, Celgene, and Medscape and has served on the advisory board for Incyte, CTI, Sierra Oncology, Novartis, Celgene, Roche, AOP Pharma, Geron, and Astra Zenica. H.d.L. has received grants and speakers fees from Bristol Myers Squibb and Incyte and speaker fees from Novartis. Funding Information: The authors acknowledge a Blood Cancer UK award to P.H. and H.d.L. (reference 21012 ), King{\textquoteright}s Together Rapid COVID-19 Call awards to M.H.M. and K.J.D., a Huo Family Foundation Award to M.H.M. and K.J.D., Chronic Disease Research Foundation award CDRF-22/2020 to K.J.D. and M.H.M., and Wellcome Trust Investigator Award 106223/Z/14/Z to M.H.M. C.G. was supported by the MRC-KCL Doctoral Training Partnership in Biomedical Sciences ( MR/N013700/1 ). Fondation Dormeur , Vaduz funded equipment to K.J.D. ",
year = "2021",
month = nov,
day = "8",
doi = "10.1016/j.ccell.2021.10.002",
language = "English",
volume = "39",
pages = "1448--1449",
journal = "CANCER CELL",
issn = "1535-6108",
publisher = "Cell Press",
number = "11",
}
